Drug Trial Radar · NCT03681184
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Last checked: Nov 20, 2026Latest source record: Aug 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Nov 27, 2018
Primary completion
Nov 5, 2019
Study completion Jan 12, 2024
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Sep 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
Conditions
- Primary Hyperoxaluria Type 1 (PH1)
Interventions
PlaceboDrug
Placebo by SC injection
LumasiranDrug
Lumasiran by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6Time frame: Baseline to Month 6
Locations
17 sites in 8 countries. Site status is shown where the registry gives one.
Clinical Trial Site
San Diego, California
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
New York, New York
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Lyon, France
Clinical Trial Site
Paris, France
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Haifa, Israel
Clinical Trial Site
Jerusalem, Israel
Clinical Trial Site
Nahariya, Israel
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
Bern, Switzerland
Clinical Trial Site
Dubai, United Arab Emirates
Clinical Trial Site
Birmingham, United Kingdom
Clinical Trial Site
London, United Kingdom
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.